Indications
Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.
Composition
- Active substance
- levodopa, carbidopa, entacapone
- International name (INN)
- levodopa;carbidopa;entacapone
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Stalevo
- Active substance
- levodopa, carbidopa, entacapone
- ATC code
- N04BA03
- Group
- Nervous system
- Therapeutic area
- Parkinson Disease
- Marketing authorisation holder
- Orion Corporation